trial · primary record
RC148 plus Telisotuzumab adizutecan
Patients With Unresectable Colorectal Cancer Requiring First-Line or Second-Line Therapy
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 412 |
| Primary completion | 2030-01 |
| Primary endpoint | ORR as assessed by the Investigator per RECIST v1.1 |
| Registry ID | NCT07895355 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:56.412Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07895355
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.